H. Lundbeck AS (LTS:0ND5)
kr 43.41995 0.11914 (0.28%) Market Cap: 41.36 Bil Enterprise Value: 39.36 Bil PE Ratio: 13.51 PB Ratio: 1.51 GF Score: 53/100

H Lundbeck A/S at JPMorgan Healthcare Conference Transcript

Jan 09, 2023 / 09:30PM GMT
Release Date Price: kr26.66 (+0.15%)
James Daniel Gordon
JPMorgan Chase & Co, Research Division - Senior Analyst

Good afternoon. I'm James Gordon, JPMorgan European pharma and biotech analyst. And today, I've got the pleasure of introducing the Lundbeck presentation. So we're going to hear from Lundbeck's CEO, Deborah Dunsire, and we've got a 20-minute presentation, and then we'll leave 20 minutes for Q&A, which is going to take place in here. And you can try and log your questions on the website or you can put up your hand, and we'll take your question.

With that said, thanks a lot for joining us, Deborah. Look forward to the presentation.

Deborah Dunsire;S;President;CEO
H. Lundbeck A

/-&

Great. Thank you, James. Well, happy new year to everybody. It's great to be back in-person in a lot of ways, and I'm very, very happy to be presenting Lundbeck here today. So you've seen our forward-looking statements, so I don't have to spend any time on those.

It's exciting times to be active in neuroscience, and Lundbeck has

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot